HUMANIZED MOUSE MODELS

Versatility and reproducibility in oncology studies.

Humanized mouse models are the swiss-knives of preclinical models: they can be used to identify tumor stem cells, investigate tumor cell biology, identify and test potential drugs, and get a better insight on metastasis. Finding a CRO that provides you with the study designs and models you need for your immunological trials can be as daunting as the trials themselves: Hu-PBL-scid models ensuring flawless memory T cells, or Hu-SRC-scid models which will guarantee the multilineage development of hematopoietic stem cells, is challenging at best.

As the need for humanized models grows exponentially with all advances made in immunology, the lack of reliable, cost-effective platforms is proving to be an obstacle that many are finding hard to overcome. But not at Pharmalegacy.

Humanized Mouse Models

Models / Services

The development of CD34+ humanized mouse model:


We reconstitute NOG/NPG immunocompromised mice with a human hematopoietic system via engraftment of human cord blood CD34+ cells. The level of humanization is determined by human CD45+ cell ratio, which ranges from 40% to 60% with the majority of T and B cells in the peripheral blood after 16 weeks engraftment. Any mouse with >15% hCD45+ cells is considered as a valid model according to varies dosing studies. The CD34+ humanized mice have the longest research span of over a year without graft-versus-host disease.

Level of “humanization” (human CD45+ cells ratio) ranged between 40%-60%, with little variation between batches of hCD34+ HSC transplanted animals.


Level of human T cells reconstitution in peripheral blood increased continuously post hCD34+ HSC transplantation.

Availability of human tumor cell lines

Tumor Type Cell Lines Validated Tumor Type Cell Lines Under Validation
Melanoma

A375

SK-MEL-5

NSCLC

EBC-1

NCI-H226

Epidermoid Carcinoma A431 Melanoma

SK-MEL-28

A2058

Lung Cancer Cell NCI-H1975

HCC-827

A549

Glioma U251MG
Breast Cancer

HCC1954

MDA-MB-231

JIMT-1

Colon Cancer HT29
Gastric Cancer MKN45

NCI-N87

Lymphoma Raji
Myeloma RPMI8226
Glioma U87MG

 

Case Study: Immune Checkpoint Inhibitors-Evaluating mAb PD-1/PD-L1 in HCC-827 Model


Case Study: Immune Checkpoint Inhibitors-Evaluating mAb PD-1 in U87MG Model

Case Study: Combination Therapy-Evaluating mAbs PD-1 and EGFR in HCC-827 Model

Case Study: Bi-Specific Ab

Evaluating Bi-Specific Ab in NC1-N87 Model

Evaluating Bi-Specific Ab in HCC827 Model

Case Study: Oncolytic Virus

Evaluating Oncolytic Virus in HCC827 Model

The Development of CD34+ Humanized Mouse Model

Human T Cell Proliferation in PB of HCC827 hCD34+ Humanized Model

PD-1/PD-L1 Combination Therapy in HCC827 hCD34+ Humanized Model

PD-L1&VEGF Combination Therapy in U87MG hCD34+ Humanized Model

PD-1&HER-2 Combination Therapy in HCC1954 hCD34+ Humanized Model

PD-1/PD-L1-VEGF Bi-Specific Abs Therapy in hCD34+ Humanized Model

Oncolytic Virotherapy in hCD34+ Humanized Model

Cell Lines Validated in hCD34+ Humanized Model

Production of 2nd Humanized Mice at Pharmalegacy

NO WAITING cohorts from Mix-donor HSCs

Reconstitution of Human Immune Systems in 2nd Humanized Mice



HCC827 in Different Batches of 2nd Humanized Mice



Efficacy Study in A549 2nd Humanized Mice Model




Two different PBMC delivery approach:

1. Pre-mix PBMC and tumor cells then inject by subcutaneously;
2. Before tumor cell inoculation, injection of PBMC by intravenously or intraperitoneally.

Readouts:

body weight, tumor growth inhibition, annotation of tumor infiltrating leukocytes (TIL) and tumor cells.

Committed to quality:

  • Capacity to house over 20,000 rodents and large animals
  • Scientific staff with an average of over 15 years of pharmacology experience.
  • FDA Part 11 compliant
  • 24/7 access to PharmaLegacy representatives.

Never settle for less in your preclinical oncology trial. Contact us at PharmaLegacy let’s talk about your expectations, and how we can exceed them together.

Contact Us

Top Pharmaceutical Companies Trust PharmaLegacy for their Oncology Trials

“The study they delivered on a very reasonable budget was top notch […] The model was executed flawlessly.”

See why a top-20 pharmaceutical company trusts PharmaLegacy for their preclinical immuno-oncology trials.





    Immuno-Oncology-Case-Study-Brochure Image

    We’re ready when you are.

    Tell us your pharmacology challenges.